ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2064

Increase in IL-31 Serum Level in Recent Onset Spondyloarthritis – Data from the DESIR Cohort

Nicolas Rosine Jr.1, Adrien Etcheto2, Anna Moltó3, Yassine Taoufik4, Houria Chavez4, Christian Roux5, Karine Briot5, Maxime Dougados6 and Corinne Miceli5, 1Rheumatology Department, Hôpital Kremlin Bicêtre, Paris, France, 2Rheumatology B, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 3Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, 4Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 5Rheumatology B Department, Hôpital Cochin, Paris, France, 6Rheumatology B Department,, Paris-Descartes University, APHP, Cochin Hospital, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: interleukins (IL) and spondylarthritis, WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: IL-31 is a newly-described cytokine mainly produced by activated Th2 cells. IL-31 acts through IL31-RA and oncostatin heterodimeric receptors that activate STAT3 and STAT5. So far, IL31 has been mainly involved in airway hypersensitivity and atopic dermatitis. More recent data suggest its involvement in psoriasis and inflammatory bowel disease. We aimed to assess IL-31 serum levels in patients with recent onset axial spondyloarthritis (SpA).

Methods: The DESIR cohort is a prospective, multicenter French cohort of 708 patients with early inflammatory back pain (IBP) (duration >3 months and <3 years) suggestive of AxSpA (mean age 33.8 years; 53.8% women, 57% fulfilled the ASAS criteria). IL-31 and sCD40L were assessed using the multiplex and high sensitive 17-Plex ELISA (Bio-Plex Pro Human Cytokine 17-Plex Immunoassay, BioRad). Serum levels were assessed at baseline in 3 subgroups of patients: i. patients from the DESIR cohort fulfilling the ASAS criteria (ASAS + group, n=443); ii. IBP patients from the DESIR cohort not fulfilling the ASAS criteria (ASAS – group, n= 265); iii. Healthy controls age and sex-matched to a random sample of the DESIR cohort patients (control group, n=80).

Results: IL31 was significantly increased (p<0,001) in the ASAS+ group (median= 7.7 pg/ml ± 15.4, mean 12.6 pg/ml) and ASAS – group (median 6.3 pg/ml ± 16, mean = 11.3 pg/ml) compared to the control group (median=0.0±3.1, mean=1.1 pg/ml). IL31 was correlated with sCD40L(r=0.62; p<0.0001), with DKK-1 (r=0.27; p<0,001), and weakly with IFNg (r=0.12; p=0,016). Patients exhibiting a high level of IL31 had increased CRP (p=0.04), a mSASSS score <1: Yes 7.7 ± 10.7 versus No 13.02±15.07 (p=0.005), and a diagnosis of osteoporosis: Yes 14.1±16.7 versus No 10.7±13.6 (p=0.005). These results were confirmed in the multivariate analyses with a significant and independent association between IL31 and IFNg (p<0.0001), sCD40L (p<0.0001), DKK1 (p=0.02) serum levels, and osteoporosis (p=0.002).

Conclusion: IL31 serum levels are correlated with cytokines involved in a Th1 polarization. IL31 is also significantly correlated with the Wnt signaling inhibitory protein DKK-1 and associated with the osteoporotic phenotype of the patients. These preliminary results suggesting that IL31 might be involved in bone loss observed among SpA patients need to be confirmed in more severe forms of the disease.


Disclosure: N. Rosine Jr., None; A. Etcheto, None; A. Moltó, None; Y. Taoufik, None; H. Chavez, None; C. Roux, None; K. Briot, None; M. Dougados, None; C. Miceli, None.

To cite this abstract in AMA style:

Rosine N Jr., Etcheto A, Moltó A, Taoufik Y, Chavez H, Roux C, Briot K, Dougados M, Miceli C. Increase in IL-31 Serum Level in Recent Onset Spondyloarthritis – Data from the DESIR Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/increase-in-il-31-serum-level-in-recent-onset-spondyloarthritis-data-from-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increase-in-il-31-serum-level-in-recent-onset-spondyloarthritis-data-from-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology